Business
Realisation-c£1.5m on sale of shares in Incanthera
Realisation-c£1.5m on sale of shares in Incanthera.
About this update from Immupharma Plc
[{"type":"text","content":"\n\n \nRNS | 3 June 2024\n\n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\n \nRealisation of c£1.5 million on sale of shares in Incanthera plc\n \nImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that it has realised gross proceeds of c£1.5 million on the sale of its entire holding of c9.9 million shares in Incanthera plc.\n \nFollowing this transaction, ImmuPharma retains c7.3 million warrants in Incanthera plc which have an exercise price of 9.5p and exercise expiry date of 6 September 2024.\n \n\n\n\n\nFor further information please contact:\n \n\n\n\n\nImmuPharma PLC (www.immupharma.com)\nDr Tim Franklin, COO\nLisa Baderoon, Head of Investor Relations\n\n\n+44 (0) 207 206 2650\n \n+ 44 (0) 7721 413496\n \n\n\n\n\n\n\n\n\n\n\n\n\n \nSPARK Advisory Partners Limited (NOMAD)\nNeil Baldwin\n \nStanford Capital Partners (Joint Broker)\nPatrick Claridge, Bob Pountney\n \nSI Capital (Joint Broker)\nNick Emerson\n\n\n \n+44 (0) 203 368 3550\n \n \n+44 (0) 203 650 3650/51\n \n \n+44 (0) 1483 413500\n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNotes to Editors\n \nAbout ImmuPharma PLC\n \nImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.\n \nFor additional information about ImmuPharma please visit www.immupharma.co.uk\n \nImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.\n\n","length":5982,"tagName":"div"}]